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Abstract 
Cellular communication and signaling are essential for the organization, 
preservation, and proper functioning of different cell types in multicellular organisms. 
Recently the study of the mechanisms for intercellular communication mediated by 
extracellular vesicles (EVs) has been the focus of research within the scientific 
community. 
Extracellular vesicles exert diverse physiological and pathophysiological 
functions by serving as vehicles of horizontal transfer of protein, lipids, DNA, and RNA 
between cells. These cellular interaction processes can influence, among others, the 
developmental patterning of tissues, as the case of vascular smooth muscle cells 
(VSMCs) differentiation with the generation of EVs playing an important role in vessel 
calcification. These calcification-competent EVs are thought to create the first nidus for 
calcification through the clustering of calcium-phosphate (Ca/P) minerals within the 
extracellular matrix of blood vessels, resembling skeletal mineralization.  
Extracellular vesicles are a promise and fresh therapeutic area for the delivery of 
different synthetic and biological molecules in cellular therapy. Indeed, EVs-based drug 
delivery is an experimental field that has evolved greatly in the past few years, with an 
especial attention for miRNA therapeutics. The potential advantages over the existing 
synthetic delivery systems are attracting much attention, adding a new pharmacological 
mean of intervention using EVs as an encouraging drug transportation system in the 
treatment of cardiovascular diseases. 
However, in order to speed up the clinical application of EVs as the next 
generation of targeted gene delivery vehicles, much work still needs to be done focusing 
the features of EVs-mediated vascular calcification in order to highlight potential 
therapeutic targets within this pathology and achieve progress in diagnosis and 
treatment in the cardiovascular filed.  
 
 
Keywords: Cellular communication; Extracellular vesicles; Vascular 
calcification; Cardiovascular disease. 
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Resumo 
A comunicação e sinalização celular são essenciais para a organização, 
preservação e bom funcionamento dos diferentes tipos de células dos organismos 
multicelulares. Recentemente, o estudo dos mecanismos de comunicação intercelular 
mediados por vesículas extracelulares têm sido foco de diversos estudos na comunidade 
científica. 
As vesículas extracelulares exercem diversas funções fisiológicas e 
fisiopatológicas ao servir como veículos para a transferência horizontal de proteínas, 
lípidos, ADN e ARN entre as células. Estes processos de interação celular podem 
influenciar, entre outros, o padrão de desenvolvimento de tecidos, como é exemplo a 
diferenciação das células musculares vasculares lisas com a geração de vesículas 
extracelulares, que desempenham um papel crucial na mediação da calcificação 
vascular. Estas vesículas extracelulares, competentes para a calcificação, criam o 
primeiro sítio de calcificação através da aglomeração de minerais de cálcio-fosfato 
(Ca/P) na matriz extracelular dos vasos sanguíneos, similar à mineralização do osso.  
As vesículas extracelulares representam uma promissora e nova área terapêutica 
para o transporte de diversas moléculas sintéticas e biológicas na terapia celular. O 
transporte de fármacos baseado nas vesículas extracelulares é um campo experimental 
que evoluiu muito nos últimos anos, com especial atenção para a terapêutica com 
miRNAs. As potenciais vantagens em relação aos existentes sistemas sintéticos de 
transporte estão a atrair muita atenção, revelando uma nova medida farmacológica de 
intervenção usando as vesículas extracelulares como um sistema encorajador de 
transporte de fármacos no tratamento de doenças cardiovasculares. 
De modo a acelerar a aplicação clínica das vesículas extracelulares como a 
próxima geração de veículos de transporte direcionados, muito trabalho tem ainda que 
ser feito de modo a evidenciar as características da calcificação vascular mediada pelas 
vesículas com vista a destacar potenciais alvos terapêuticos dentro desta patologia e 
desta forma, progredir no diagnóstico e tratamento no campo cardiovascular. 
 
Palavras-chave: Comunicação celular ;Vesículas extracelulares; Calcificação 
vascular; Doença cardiovascular.
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Resumo Alargado 
As células utilizam vários meios de comunicação de modo a assegurar a troca de 
materiais e a transferência de informações com vista o desenvolvimento, reparação e 
sobrevivência dos tecidos. Para alcançarem o sucesso na realização das suas funções 
celulares e manterem a homeostase dos seus tecidos, as células recetoras têm de possuir 
a capacidade de receber e interpretar os sinais celulares recebidos. 
As vesículas extracelulares são uma família de partículas nano-esféricas, de 
tamanho variável, libertadas para o ambiente extracelular por meio de uma célula mãe. 
Retratam um novo tipo de sinalização intercelular que pode ser encontrada tanto em 
células procariotas como eucariotas. Estudos revelaram que as vesículas extracelulares 
são secretadas pela maioria, se não por todos os tipos de células humanas e podem, 
igualmente, ser encontradas em vários fluídos corporais, incluindo o sangue. De modo a 
proteger o conteúdo da carga interna da degradação enzimática existente nestes fluídos, 
a membrana exterior das vesículas é formada por uma bicamada lipídica protetora. 
Apesar da sua descoberta remontar aos anos 60, apenas recentemente ficou claro 
que as vesículas extracelulares são veículos fundamentais para a sinalização celular, 
capazes de transmitir informações complexas a longas e curtas distâncias em relação à 
sua célula de origem. 
Embora as vesículas extracelulares sejam amplamente classificadas em três 
classes principais, tendo em consideração o seu tamanho e mecanismos de biogénese 
(exossomas, microvesículas e corpos apoptóticos), existe alguma discrepância na 
literatura relativamente à sua nomenclatura. Isto é, podem ser encontradas algumas 
disparidades, onde frequentemente as vesículas extracelulares são utilizadas como 
sinónimo de matrix vesicles (MVs). Estas últimas são na verdade um subtipo de 
vesículas, que em condições fisiológicas normais são produzidas por células ósseas e 
têm a capacidade de reter cristais de Ca/P, promovendo a mineralização no tecido ósseo. 
Devido ao facto das vesículas extracelulares, envolvidas na deposição patológica de 
minerais nos vasos, se assemelharem às MVs encontradas nas células ósseas, elas são 
comummente designadas por MVs no contexto vascular. 
 No interior da camada média dos vasos sanguíneos residem as células musculares 
vasculares lisas que possuem a capacidade extraordinária de alterar o seu fenótipo entre 
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um estado celular contrátil e um sintético. Ao contrário de muitas outras células no 
corpo humano, tais como as cardíacas e ósseas, as células musculares vascular lisas não 
maturam totalmente, retendo esta capacidade de diferenciação fenotípica durante o seu 
tempo de vida. Este processo tem sido implicado como um dos principais mecanismos 
de libertação de vesículas extracelulares, com alto poder de calcificação, para o meio 
extracelular dos vasos sanguíneos. 
As vesículas extracelulares secretadas para o espaço extracelular podem 
potencialmente transportar dentro do seu conteúdo celular proteínas, ácidos nucleicos e 
receptores de membrana, provenientes da sua célula mãe. Para além desta 
particularidade, o conteúdo celular transportado pelas vesículas varia ainda de acordo 
com o tipo de célula envolvida e com as condições fisiológicas ou patológicas existentes 
no momento da sua formação e secreção celular. Em condições normais, as vesículas 
extracelulares derivadas das células musculares vasculares lisas não apresentam um 
poder de calcificação porque contêm no seu interior inibidores da mineralização e 
microARN regulatório como forma de sinalização, que previne o processo de 
diferenciação destas células.  
No entanto, sob um contexto patológico, a sinalização celular mediada pelas 
vesículas torna-se comprometida, assistindo-se a um desequilíbrio dos inibidores de 
calcificação e à promoção de um ambiente favorável à diferenciação das células 
musculares vasculares lisas. Na matriz extracelular dos vasos sanguíneos, estas células 
começam a libertar vesículas com alto poder de calcificação, isto é, vesículas capazes de 
reter cristais de Ca/P no seu interior, que formam um dos primeiros sítios de 
mineralização, com consequente propagação da calcificação vascular. 
Previamente considerada como um processo passivo de significância 
fisiopatológica limitada e como uma consequência inevitável do envelhecimento, a 
calcificação vascular entende-se pela deposição inadequada e patológica de cristais de 
Ca/P nos tecidos vasculares, representando um grande contributo para a progressão da 
doença cardiovascular, uma das principais causas de morte nos países industrializados. 
A cada ano, as doenças cardiovasculares causam 3,9 milhões de mortes na Europa, 
representando 45% de todas as mortes. Dada a associação entre a calcificação e os 
outcomes cardiovasculares, é urgente uma melhor compreensão desta patologia, com 
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destaque principal sobre os mecanismos que levam à deposição de minerais e ao seu 
crescimento progressivo na parede dos vasos sanguíneos desde os primeiros estadios. 
A calcificação vascular pode ainda ocorrer nos vasos sanguíneos, válvulas e 
tecidos cardíacos, manifestando-se sob a forma de calcificação aterosclerótica, 
calcificação da camada média, também conhecida por esclerose média de Monckeberg, 
calcifilaxia (um subtipo de calcificação da camada média) e calcificação das válvulas 
cardíacas. 
Apesar dos vários estudos que focam os mecanismos básicos desta complexa 
patologia, ainda existem alguns processos que precisam de esclarecimento adicional. No 
entanto, a calcificação vascular é atualmente interpretada como uma resposta patológica 
multifacetada a diferentes estímulos que podem surgir por diversos mecanismos 
fisiopatológicos, tais como níveis séricos elevados de cálcio e fosfato, perda de 
inibidores de calcificação vascular, diferenciação e/ou morte das células musculares 
vascular lisas e a libertação de vesículas extracelulares com poder de 
mineralização/calcificação. 
Uma vez que representam vetores naturais de informação biológica, capazes de 
alterar mecanismos fisiológicos através da transferência de mediadores benéficos ou 
prejudiciais à célula recetora, diversos são os estudos que evidenciam as vesículas no 
processo de calcificação vascular. De facto, pelo seu papel fundamental nos 
mecanismos de calcificação e pela capacidade de transferir o seu conteúdo celular 
através de mecanismos naturais de absorção endógena, a promissora aplicação clínica 
das vesículas como sistemas de transporte direcionado de fármacos tem sido uma área 
de investigação intensa. Adicionalmente, como o seu conteúdo celular reflete o estado 
fisiológico da célula mãe, estas vesículas podem igualmente ser aplicadas em 
diagnóstico clínico como biomarcadores patológicos. 
Pesquisas futuras dentro desta linha de pensamento poderão levar a uma nova 
geração de terapias direcionadas para os múltiplos pontos de intervenção da formação 
da microcalcificação dos vasos sanguíneos, onde as vesículas serão uma escolha 
terapêutica capaz de atingir células específicas de modo a prevenir ou retardar os 
resultados cardiovasculares da calcificação vascular. 
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No entanto, é ainda necessária muita investigação com vista a completar a 
compreensão atual dos mecanismos de calcificação extracelular mediados pelas 
vesículas. Um passo adiante neste campo passará inegavelmente pelo desenvolvimento 
de protocolos padronizados para o isolamento das vesículas, a fim de assegurar que a 
caracterização documentada possa permanecer comparável entre diferentes laboratórios. 
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1 - Intercellular Communication 
During the course of evolution, both prokaryotes and eukaryotes developed 
elegant cell-to-cell communication strategies to adapt to stimuli created by the 
surrounding environment. The development of multicellular organisms most likely 
began when cells remained associated in small colonies after division, instead of 
separating into individual cells. A few prokaryotes and several unicellular eukaryotes, 
such as many fungi and slime molds, exhibit such rudimentary social behavior. The full 
flowering of multicellularity, however, occurred in eukaryotic organisms, whose cells 
became differentiated and organized into groups or tissues in which cells perform 
specialized functions (1). 
Cellular communication is considered one of the most important regulatory 
mechanisms for cell growth, differentiation and tissue remodeling that allows 
multicellular organisms to maintain regular cellular functions.  In fact, a key step in the 
evolution of multicellularity was indeed the ability of cells to contact tightly and 
communicate specifically with each other (1). 
Cells use several means of communication for the exchange of materials and the 
transfer of information in order to maintain tissue homeostasis, development, repair and 
survival. To succeed their inner functions, an appropriate communication through 
signals must be present and capable of being interpreted by specific and complex 
machinery in the recipient cell (1). Regardless the nature of the signal, the target cell 
responds by means of a specific protein called receptor that specifically binds to the 
signaling molecule and then initiates a response in the target cell. In most cases the 
receptors are transmembrane proteins on the target cell surface, and when they bind to 
an extracellular signaling molecule, they become activated generating a cascade of 
intracellular signals that alter the behavior of that specific cell. In some cases, however, 
the receptors can be inside the target cell and the signaling ligand has to be incorporated 
by the cells for activation (1,2). 
1.1 - Types of Intercellular Communication 
Cells have evolved a variety of signaling mechanisms to accomplish the 
transmission of important biological information. Classically in cell biology, eukaryotic 
cells communicate directly, requiring cell to cell contact, or indirectly, via soluble 
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molecules secreted by one cell which are then carried away to target cells. Depending 
on the distance that the signaling molecule has to travel, intercellular communication 
can be classified in two types, the direct cell to cell communication and the distant cell 
communication (2). 
The direct cell-to-cell signaling can be mediated by juxtacrine interactions 
between touching cells, in which signals can be transmitted by junctional complexes 
including tight junctions, desmosomes, adherens and gap junctions. On the other hand, 
distant cell communication is carried out by signaling molecules that can be carried far 
afield to act on distant targets (long-range) or by local mediators affecting the cells in 
the immediate environment of the signaling cell (short-range) (2). These soluble factors 
can act on the cell itself (autocrine signaling) or influence both neighboring (paracrine 
signaling) and distant cells (endocrine signaling) allowing cellular communication in 
the absence of physical contact (3). 
Recently a distant intercellular communication mechanism mediated by 
extracellular vesicles has gained a growing interest among the scientific community. 
Extracellular vesicles (EVs) are a new type of intercellular signaling, representing an 
universal and highly conserved active cellular function that can be found in both 
prokaryotics and eukaryotics cells (3).  
Despite their discovery decades ago, only now has become clear that these 
vesicles are important vehicles of cellular signaling, capable of carrying out complex 
information through autocrine, paracrine and even endocrine ways (3). EVs released by 
cells into the extracellular space can potentially reach distant tissues, transporting within 
their cargo proteins, lipids, nucleic acids and membrane receptors from their origin cell. 
This functional EV’s content differs not only according to its cell of origin cell function 
but also with the specific physiological and pathological conditions existing at the time 
of packaging and secretion (4). In the last decade, the number of studies recognizing 
EVs as a crucial and integral part of cellular microenvironment and communication has 
grown exponentially revealing a new scenario in terms of understanding signal and 
molecule transfer between cells, not only locally, but also over long distances (5,6). 
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1.1.1 - Extracellular Vesicles  
1.1.1.1 - Biological Properties and Relevance 
Extracellular vesicles are a family of heterogeneous and spherical nano sized 
particles released by cells into the extracellular environment, differing in terms of the 
contents, size and formation mechanisms. EVs are formed by a lipid bilayer membrane 
that encloses a small organelle free cytosol, containing proteins and nucleic acids 
present on the EV’s origin cell (7).  
Due to their rich composition and capacity to interact with other cells, EVs play a 
functional role in many biological processes, having the remarkable capability to deliver 
combinatorial information to multiple cells all over the body. However, very little is 
known about the role of EVs in homeostasis maintenance in normal physiological 
conditions. EVs intrinsic cell functions and regulation only started to be highlighted 
recently (8). 
Studies reveal that EVs are secreted by most, if not all,  human cell types, like 
epithelial cells, fibroblast, hematopoietic cells, immune cells, tumor cells, and even 
stem cells. In addition, EVs can be found  in several body fluids, including urine, saliva, 
nasal fluid, amniotic fluid, breast milk, seminal plasma, bronchoalveolar fluid, bile, 
cerebrospinal fluid, and in blood (3). 
Depending on their biogenesis and size EVs are classically classified in exosomes, 
microvesicles, and apoptotic bodies (ABs). Their lipid bilayer membrane, containing 
various proteins and receptors, protects their bioactive internal cargo from the 
enzymatic degradation, present in the extracellular environment, conceding them the 
ability to deliver both physiological and pathological information  (9).   
It has been studied and documented that the transfer of RNA and miRNA between 
cells are involved in the change of target cell phenotype and microenvironment, 
reprogramming their functions by pleiotropic effects, potentially leading to several 
pathological conditions (10). Since EVs are capable of becoming enriched with 
molecules expressed by the cells of origin, current studies have focused on the EVs 
capacity to induce epigenetic changes in target cells, resembling the origin cell. In this 
context, several studies have been showing that EVs play a fundamental role in the 
transfer of genetic information between cells promoting cellular differentiation  (11,12).  
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The understanding of why cells release vesicles, how vesicles play a role in 
intercellular communication, how vesicles may contribute to cellular homeostasis, and 
especially how vesicles can mediate pathophysiological conditions, reveals a very 
complex and sophisticated role of vesicles both in health and disease. A growing body 
of evidence suggests that EVs are truly involved in physiological as well as pathological 
processes, and the interest in their biological role and clinical application is increasing 
exponentially (13). 
1.1.1.2 - EVs Research Field - Historical Notes 
The discovery of cell derived extracellular vesicles followed the introduction of 
the transmission electron microscope, and their relevance occurred simultaneously in 
many physiological settings, without the realization that this form of cellular function 
and communication is an universally shared cell biological property (14). 
In history of cell biology, the detection of these particles can be traced back to 
initial researches on blood coagulation. Originally reported in 1946 by Chargaff and 
West, EVs were observed as procoagulant platelet-derived particles in normal plasma 
(15). In the same area, Peter Wolf identified these particles as part of a disposal 
mechanism to discard unwanted materials from platelets, labeling them as “platelet 
dust”, in 1967 (12). In the same year, the releasing of extracellular vesicles during the 
physiological mineralization processes in bones was discovered and reported by and 
Bonucci  (17), and in 1969 by Anderson (16), that originally termed them as matrix 
vesicles. Twenty years later, the  research group led by Rose Johnstone introduced for 
the first time the term exosomes when studying reticulocytes undergoing maturation 
into red blood cells (11). 
Later, Graça Raposo and colleagues demonstrated that these type of vesicles, 
isolated from Epstein-Barr virus transformed B lymphocytes, were antigen-presenting 
and able to induce T-cell responses. These studies provided the basis for the hypothesis 
that exosomes could play an active role in intercellular communication, particularly in 
the immune system, inciting the very first attempt of using EVs as a new type of 
anticancer therapy in humans (19). 
The discovery of apoptotic bodies and microvesicles came later, in 1972 by John 
Kerr (20) and 1991 by Janet Stein (21), respectively. Since then apoptotic bodies have 
been largely related with programmed cellular death, and their biological role in cellular 
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communication is still unclear. By contrast, microvesicles have been widely 
investigated and found to be secreted by various cell types.  Their role in cellular 
communication and differentiation is nowadays an extensive research field, alongside 
with exosomes. 
Findings that EVs could in fact enclose RNA and microRNA led to an increasing 
interest of EVs as novel mediators of intercellular communication (22).  In 2011, the 
International Society of Extracellular Vesicles (ISEV) was created as a need for 
standardization and clarification of several aspects concerning the EVs field, such as the 
nomenclature, purification and characterization methodologies (3).  
Nowadays, intensive investigation has highlighted the role of EVs in many 
pathological conditions, such as lung injury (7), liver diseases (23), neurodegenerative 
diseases (24), cancer (25). The increased interest in EVs, allied to the development of 
improved isolation and detection methods, led to novel insights into possible clinical 
applications of these vesicles. In these last two decades, cardiovascular disease was one 
of the clinical areas most intensely studied in the extracellular vesicles field (26). 
1.1.1.3 - EV’s Characterization and Current Classification 
The small differences in physical properties and composition of EVs, the need of 
high sensitivity techniques to detect them, the lack of standard isolation methodologies 
and the fact that the same cell type may even secrete different types of vesicles makes 
EVs detection and isolation very challenging. Furthermore, the content and number of 
EVs secreted depends on the cells they originate, the stimulus of production and the 
mechanism of vesicle generation (27). 
EVs can be categorized into three main classes based on their size and biogenesis 
pathways. Although in the literature diverse scales are used by different authors, it is 
commonly accepted that microvesicles diameter can range from 50 nm to 1000 nm, 
exosomes from 10 nm to 100 nm, and apoptotic bodies that greatly vary in size can have 
between 1000 nm and 5000 nm of diameter. Overall EVs comprise a wide variety of 
vesicles with different cargos, and with overlapping in size for different EVs types (13). 
Apoptotic bodies also called apoptotic blebs, apoptotic bodies or apoptosomes are 
membrane limited vesicles that can be classified as a subclass of EVs. They are released 
through protrusions and fragmentation of the cell membrane of cells undergoing 
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apoptosis. These particles are the largest extracellular vesicles harboring cell organelles 
and nuclear fractions surrounded by a permeable membrane. Under specific conditions, 
ABs can be more abundant than exosomes or microvesicles. A feature present in these 
vesicles is the externalization of phosphatidylserine (PS), a phospholipid component of 
the cellular membrane, a phenomenon also seen in microvesicles (28). 
Their rapid elimination promoted by phagocytic cells such as macrophages, as a 
respond to specific signaling molecules, makes this population less well characterized, 
and the information on the potential role of apoptotic bodies in cardiovascular diseases 
is very scarce (23).  
Microvesicles also found in literature as membrane particles, ectosomes or 
shedding microvesicles, are cell surface derived EVs usually larger than exosomes. 
They are generated by direct budding and subsequent fusion of the plasma membrane 
into the extracellular environment, comprehending a cytoskeleton remodeling and 
externalization of PS, like ABs. When the plasma membrane is activated by extrinsic 
stimuli, membranous globular extensions are shed from the plasma membrane surface 
and subsequently released to the extracellular space, as illustrated in Figure 1.1. This 
releasing mechanism appears to be increased in inflammatory conditions (9). 
Exosomes are the smallest extracellular vesicles although no clear cut-off value 
separates microvesicles from exosomes in terms of size. They are present in many, if 
not in all biological fluids, and are the extracellular vesicles that have received most 
attention over the past few years (28). Additionally, their physicochemical properties 
and biological function are well documented in contrast to other types of vesicles (30). 
Exosomes are intraluminal nano vesicles generated from multivesicular bodies 
(MVBs), a late endosomal compartment from the cell trafficking machinery. The 
biogenesis of exosomes is typically thought to occur in a twostep process, firstly 
involving the formation of cytoplasmic MVBs that gather and  package molecules into 
luminal membrane bound structures, and secondly by their subsequent fusion with the 
plasma membrane which releases these internal vesicles as exosomes enabling their 
diffusion into the extracellular environment (8), as represented in Figure 1.1. 
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In the majority of EVs studies, clinical interests have been focused on exosomes 
and microvesicles rather than ABs, given that vesicles and their compositions derived 
from living cells can potentially play more crucial functions in the development of 
pathological conditions (7). 
In order to confirm the presence of EVs and identify the specific subtype in 
isolated preparations, researchers have struggled to identify what could be designated as 
EV’s marker proteins. To confirm the presence of EVs, there is a subset of biomarkers 
existing in either EV’s membrane or cytosol that helps to separate EVs from non-
vesicular entities present in preparations. (31). However, studies have shown that these 
markers are not common to all EVs subtypes, which depend and correlate to the EV’s 
cell origin functions, revealing that EV’s marker proteins can be highly variable (31). 
Indeed, the main challenge of ISEV and research groups within this field confines in the 
identification of specific markers to distinguish each of EVs subtypes (32).  
Although EVs components are different among cells, some proteins are thought to 
be essential EV’s constituents, and therefore, can be commonly found in all EVs 
Figure 1.1 - Cells produce different types of extracellular vesicles that vary in size 
and mechanism of vesicle generation. Exosomes and microvesicles are produced by 
normal and pathologic cells, while apoptosis triggers the release of apoptotic bodies. 
Exosomes have been identified to be released from multivesicular bodies during their 
fusion with the plasma membrane. Microvesicles and apoptotic bodies are shed from the 
plasma membrane through direct outward budding of the plasma membrane, which 
defines their diameter and molecular composition with the difference that ABs are 
generated from a cell undergoing apoptosis; adapted from (29). 
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regardless of their origin. These molecules include tumour susceptibility gene 101 
(TGS101) (31), and testraspanins such as CD9 and CD63 (33). 
Despite the field of EVs research has not developed enough in order to identify a 
list of EV-specific markers that clearly distinguish each EVs subtypes (34), some 
protein markers are often used  in the literature as a mean to classify the EVs subtypes 
present in a mixed population.  
ABs are distinctly different from exosomes and microvesicles because they 
abundantly contain histones associated with membranes that float at high sucrose 
densities and because they are very heterogeneous in size and morphology when 
observed by electron microscopy (35).  
Microvesicles are enriched in phosphatidylserine, integrins, selectins, and CD40 
ligand (36). However, distinguish between exosomes and microvesicles is very 
challenging. Although there are some differences in the size and composition of these 
EVs, in a mixed EVs population it remains impossible to completely separate exosomes 
and microvesicles with the currently available purification methods. These 
methodological issues represent one of the biggest problems in terms of EVs isolation 
and characterization (37,38). 
Common protein markers used to identify the presence of exosomes in an EVs 
population are components of the endosomal sorting complex required for transport,  
like ALG-2-interacting protein X (39) and TGS101 (31), heat shock proteins like 
HSP70 and HSP90 and tetraspanins CD9, CD63, CD81 (40). Due to the fact that some 
of the previous proteins are markers for the detection of EVs in general, a combinatorial 
identification of these markers is preferred rather than a single biomarker for exosomes 
characterization (32).  
Additionally, some authors defend that in order to achieve a rigorous EVs 
characterization, it is required a combination of the most common techniques used in 
EVs studies  (39), such as flow cytometry, dynamic light scattering, nanoparticle 
tracking analysis, scanning and transmission electron microscopy, atomic force 
microscopy, and detection of several marker proteins, for proper assessment of EVs 
quantity, size and features.  
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As the method used for EVs isolation can affect numbers and composition of the 
obtained vesicles, it is important to choose a suitable isolation method that ensures 
reliable and comparable measurements of EVs. Although, currently there is no 
consensus on a “model” method to isolate and/or purify EVs, and therefore no optimal 
method is uniformly used by investigators (34), Several researchers support the use of 
differential ultracentrifugation for isolation purposes and size-exclusion 
chromatography coupled with membrane filtration for subtype EVs purification from 
plasma/serum (23). 
To facilitate and improve the exchange of information between investigators, in 
2012 the ISEV defined extracellular vesicles as a generic term that can be applied to all 
types of vesicles found in the extracellular space (41). However, the use of outdated 
isolation and detection  techniques allied to in vitro studies and classification based on 
different criteria, conducted to inconsistencies found in older and some recent literature 
regarding EVs nomenclature and classification (42).  
1.1.1.4 - EVs Cellular Uptake Mechanisms 
Extensive evidence on all types of vesicles indicates that EVs are a key player in 
intercellular communication, capable of carrying out a range of signals that can have a 
significant impact on the phenotype of the recipient cells. However, for this phenotypic 
effect to occur, EVs need to fuse with target cell membranes and combine their content 
with the cytoplasmic compartment of target cells (8). 
Both release and uptake mechanisms depend on the donor and recipient cell type, 
as well as their physiological state and the conditions of the existing microenvironment.  
The internalization mechanism is proved to be an energy dependent process that 
requires a fully functioning cell cytoskeleton. There are two distinct mechanisms that 
EVs can enter a cell. They can be internalized via the fusion of the EV membrane with 
the target cell membrane or they can enter the cell by endocytosis. The uptake through 
endocytosis can be categorized into the different types of endocytotic processes 
including clathrin-mediated endocytosis, caveolin mediated endocytosis, lipid raft-
mediated endocytosis, macropinocytosis, and phagocytosis. Although endocytosis 
appears to be the principal uptake mechanism, there is little agreement as to which type 
of endocytic via is most important (43). 
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When EVs enter by endocytosis, in order to exert its cellular effects, their cargo 
must be released before being destroyed or discard by the recipient cell, since 
endosomes mature into lysosomes or are ejected out again through the MVB plasma 
membrane fusion pathway. However, this mechanism of transferring the EVs cargo out 
of the endosomal compartment is still unclear (8). 
The second EVs entrance mechanism via direct fusion of the EV membrane with 
the cell plasma membrane requires the fusion of two distinct lipid bilayers – EV and 
recipient cell membrane - in an aqueous environment. The lipid bilayers are brought 
into close proximity and a fusion pore is created permitting the two hydrophobic cores 
to mix with the delivery of EVs cargo into the recipient cell (43). 
Different cell types are able to take up EVs using various mechanisms resulting in 
either functional transfer or degradation of their cargo.  In many cases functionality of 
the EVs content depends on entry into the cytoplasm and potentially even into the 
nucleus in order to stimulated the normal cellular course or to induce their 
differentiation. This, mean that the cellular interaction established between EV and the 
target cell can determine the fate of EV’s content. (8). 
1.1.1.5 - Nomenclature Controversy 
As already described, despite the efforts of ISEV to reach an accurate and clear 
classification of EVs, there is still a lot of discrepancy in the literature regarding EVs 
nomenclature. Before the developing of further chapters, where the mechanism of 
vascular calcification will be deepened, it is crucial to clarify some of these 
inconsistencies. 
In this specific field of research is very common to found cell derived vesicles 
nomenclature according to their origin cell or tissue. For example, dexosomes are 
dendritic cell derived exosomes; oncosomes are tumor cells derived exosomes; 
prostasomes  are prostrate-derived vesicles and matrix vesicles are vesicles originated 
from bone and cartilage (44).  
Much of the knowledge regarding the role of EVs in cardiovascular calcification 
deeply relies on previously established evidence of MVs involved in physiological bone 
mineralization (14). Physiological mineralization is conducted in bone, dentin, and 
cartilage by vesicles released from specific regions of the outer membranes of bone 
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derived cells, such as chondrocytes, osteoblasts and odontoblasts. These cells mineralize 
the bone ECM through specialized spherical structures named matrix vesicles. Matrix 
vesicles have the ability to nucleate Ca/P crystals in the form of hydroxyapatite (HA) 
within bone ECM and are believed to be one of the sites of mineral nucleation that 
occur in the organic matrix of the skeletal tissues (45).  
Matrix vesicles are a sub-population of EVs that are specific to the bone tissue 
ranging from 100 to 200 nm in diameter, and their  biogenesis is thought to occur via 
budding process from its bone-parenting cell in a highly polarized manner (46).  
Matrix vesicles that mediate normal mineralization within the bone tissue, have 
high similarities with VSMCs-derived EVs known to be involved in pathological 
mineralization of blood vessels (calcifying EVs) (45). Proteomic analysis through mass 
spectrometry, has identified some common features, such as similar surface receptors, 
calcium binding proteins (annexins), cytoskeletal proteins and ECM components (45). 
These resemblances justify the fact that in literature calcifying EVs found in vasculature 
are commonly referred as MVs, sometimes contributing to a muddy reading. 
However, it is important to note that, while MVs exhibit these characteristics 
within a physiological state in skeletal tissue, calcifying EVs are features of a 
pathological environment such as the vascular mineralization process. Only in the 
presence of vascular assault, VSMCs-derived EVs are proved to become calcifying EVs 
acquiring functions that resemble MVs in bone tissue. In normal vascular settings, 
VSMCs secrete EVs that are not MVs-like, instead they promote the maintenance of 
cardiovascular homeostasis (45). 
Interestingly these calcifying EVs, responsible for vascular mineralization, have 
been recently shown to comprehend a release mechanism with an exocytosis pathway 
through MVBs, suggesting that they are in fact exosomes (47). 
As the nomenclature and methods used to isolate and purify membrane vesicles 
differ significantly between studies, in order to avoid future misreading, the term EVs as 
a collective term that encompasses all types of secreted vesicles, will be used 
throughout this work, in the same line of thought as ISEV and explicitly identify the 
subtype when necessary. 
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2 - Vascular Anatomy and Physiology 
2.1- General Characteristics of Blood Vessels 
In order to understand the pathophysiological mechanisms through which vascular 
calcification begins, an introduction of the vascular anatomy and physiology is crucial 
to better understand how EVs promote vascular calcification and induce VSMCs 
differentiation in blood vessels, which are known to be main triggers of vascular 
calcification. A deep and descriptive vascular anatomy and physiology is not intended, 
in this chapter, but rather a general approach to the main constituents of the vascular 
wall with emphasis on the main structures that will be useful to understand the 
mechanisms of vascular calcification. 
Blood vessels provide the main link between heart and tissues. They are the part 
of the circulatory system with the primarily function of transporting blood throughout 
the human body, playing a huge role in virtually every medical condition. The blood 
vessels are divided, depending on its function, location and size, into arteries, arterioles, 
capillaries, venules and veins. With the exception of capillaries and venules, the 
vascular wall is made up of three layers; the tunica intima (inner layer), the tunica media 
(middle layer) and the tunica adventitia (outer layer) (48). 
Figure 2.1- Structure of Blood Vessels. (a) Arteries and (b) veins share the same general 
features, but the walls of arteries are much thicker because of the higher pressure of the blood 
that flows through them. Adapted from (49). 
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2.1.1 - Tunica Intima 
The tunica intima also designated by tunica interna, forms the inner lining of a 
blood vessel and is in direct contact with the blood as it flows through the lumen of the 
vessel. The endothelium, the innermost layer of this tunica, is a delicate sheet of 
flattened cells that lines the inner surface of the entire cardiovascular system (heart and 
blood vessels). Despite the fact that the endothelium is an extremely complex tissue 
from the metabolic point of view, its anatomical structure is extremely simple and 
linear, a single layer of mesenchymal cells.  Until recently, endothelial cells were 
regarded as a passive barrier between the blood and the remainder of the vessel wall. It 
is now know that endothelial cells are active participants in a variety of vessel related 
activities, playing an important role in many physiological functions, including the 
control of vascular tone, blood cell trafficking, innate and adaptive immunity, among 
others (26,27). 
The endothelium exerts its function in maintaining vascular homeostasis through 
the balanced release of a number of autocrine and paracrine substances in response to 
physical, biological, and chemical stimuli. These substances, known as vasoactive 
factors, can constrict or expand the smooth muscle cells (SMCs) within the vessels wall 
to increase or decrease the blood pressure, respectively. The endothelium forms an 
important part of the vasculature and is involved in promoting an atheroprotective 
environment via the balanced production of vasoactive factors. Disruption of vascular 
homeostasis can lead to the development of endothelial dysfunction which in turn 
contributes to hypertension and eventually cardiovascular disease (51). 
The second component of the tunica intima is a basement membrane or basal 
lamina. The base membrane anchors the endothelium to the underlying connective 
tissue and also regulates molecular movement. It appears to play an important role in 
guiding cell movements during tissue repair of blood vessels walls. Finally, the 
outermost part of the tunica intima, which forms the boundary between the tunica 
intima and media, is the internal elastic lamina. The internal elastic lamina is a thin 
sheet of elastic fibers with a variable number of window-like openings that facilitate 
diffusion of materials through the tunica intima to the thicker tunica media (26,28), as 
illustrated in Figure 2.1 
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2.1.2 - Tunica Adventitia 
The outer covering of the blood vessels, also known as tunica adventitia or 
externa, consists of elastic and collagen fibers. It contains numerous nerves and 
specifically in larger vessels, tiny blood vessels that supply the tissue of the vessel wall. 
The small vessels that supply the tissues of the vessel are called vasa vasorum, and they 
are easily seen on large vessels such as the aorta. In addition to the important role of 
supplying the vessel wall with nerves and self-vessels, the tunica adventitia is also a 
support structure, as it helps anchor the vessels to the surrounding tissues (48). 
2.1.3 - Tunica Media 
The tunica media, the thickest layer in arteries, is a muscular and connective 
tissue layer that displays the greatest variation among the different vessels types. It 
comprises mainly VSMCs and substantial amounts of elastic fibers. The primary role of 
the VSMCs, which extend circularly around the lumen like a ring, is the regulation of 
the vessel lumen diameter. These cells produce the elastic fibers that allow the vessels 
to stretch and recoil under the applied pressure of the blood. Contraction and relaxation 
of VSMCs decrease and increase the diameter of the vessel lumen, respectively. (48).  
2.1.3.1 - Vascular Smooth Muscle Cells 
Smooth muscle cells are found in many organs, comprising the blood vessels, 
trachea, stomach, small intestine, and uterus. Vascular smooth muscle provides the main 
support for the structure of the vessel wall and regulation of vascular tone in order to 
maintain intravascular pressure and tissue perfusion (52). However, in physiological 
conditions, VSMCs also perform other important functions during vessel remodeling 
such as in vascular injury.  
Contrasting to other mature cell types of the human body, like skeletal and cardiac 
myocytes, VSMCs do not terminally differentiate, retaining a remarkable capability to 
modulate their phenotype during their live time. (53).  
Vascular smooth muscle cells show different phenotypes according to external 
conditions, such as aging, developmental stage, angiogenesis state, and disease. Indeed, 
they have this unique ability to switch phenotype from a contractile to a synthetic, also 
designated as osteochondrogenic state, in response to environmental stimuli (33), as 
illustrated in Figure 2.2. 
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Figure 2.2 - VSMC’s Phenotypic Plasticity. VSMCs transform their phenotypes in response to 
the surrounding environment. The contractile phenotype is a predominantly quiescent and anti-
calcifying phenotype whereas synthetic phenotypes are associated with an increased propensity 
to promote vascular calcification. Adapted from (55).   
Contractile VSMCs are characterized by low proliferation rates, high levels of 
cytoplasmic myofilaments, low rates of protein synthesis and a unique repertoire of 
contractile proteins including SM22α, SMα-actin, smoothelin, smooth muscle myosin 
heavy chain, among others. When VSMCs differentiate into the synthetic phenotype, 
normally found in embryonic and young developing blood vessels, they express 
relatively few contractile proteins, re-enter the cell cycle and become highly 
proliferative and migratory with high rates of protein synthesis and extracellular matrix 
secretion (56). 
Interestingly, the synthetic phenotype confers a survival advantage since it allows 
VSMCs to proliferate, migrate and synthesize extracellular matrix components as a 
response required for vascular repair. However, an unfortunate consequence of this 
plasticity is that it predisposes VSMCs to environmental signals that can induce adverse 
phenotypic switching into an osteoblast-like cell type. This process promote the 
development and progression of vascular calcification, as it will be deepened in the 
following chapter (35,36). 
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3 - Calcification in Cardiovascular Disease 
3.1 - Vascular Calcification  
Vascular calcification is nowadays a growing burden in Western countries, 
representing a major contributor to the progression and outcome of cardiovascular 
disease, one of the leading causes of death in industrialized countries. Each year 
cardiovascular disease (CVD) causes 3.9 million deaths in Europe accounting for 45% 
of all deaths. Overall CVD is estimated to cost the EU economy €210 billion a year. Of 
the total cost of CVD in the EU, around 53% (€111 billion) is due to health care costs, 
26% (€54 billion) to productivity losses and 21% (€45 billion) to the informal care of 
people with CVD (59). Given the association between calcification and cardiovascular 
outcomes in both patients’ health and Europe’s health economic sustainability, there is 
an urgent need to better understand the mechanisms leading to the deposition and 
growth of calcium mineral deposits in blood vessels wall from its earliest stages. 
Vascular calcification (VC) is defined as the inappropriate and pathological 
accumulation of mineral, most  in the form of insoluble calcium-phosphate (Ca/P) salts 
in the medial and/or intimal layers of the vessel wall (60). Although calcification has 
been noted in the vasculature for many decades, it was first regarded as a passive 
process of limited pathophysiological significance, mostly viewed as a natural 
consequence of aging. The introduction of new non-invasively techniques to measure 
vascular calcification, such as electron beam computed tomography, has revolutionized 
our current thinking about the risks of VC. This pathology is directly linked with blood 
vessel wall stiffness, subsequent increased pulse wave velocity and altered arterial wall 
distensibility, ultimately leading to hypertension, left ventricular hypertrophy, 
compromised coronary perfusion and heart failure (61). 
The challenges surrounding the ideal treatment of VC remain uncertain, and this 
is particularly pertinent as medicine continues to dedicate efforts in this fields to fully 
elucidate and discover novel treatment strategies to face this clinical problem (62). 
Once established, vascular calcification is progressive, and its association with 
chronic comorbidities, including coronary artery disease (CAD), peripheral arterial 
disease (PAD), diabetes mellitus (DM), and chronic kidney disease (CKD) is well 
established. Ectopic calcification, meaning the inappropriate mineralization occurring in 
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soft tissues, like arteries, vessels and heart-valves can indeed happen with normal aging, 
but it seems to be accelerated in these disease states, and related to an increased risk of 
morbidity and mortality (63). Nowadays, VC is no longer simply recognized as an 
inevitable consequence of aging, but as an active and highly complex process that 
cannot be ignored in patient’s cardiovascular clinical health. 
3.1.1 - Types of Vascular Calcification  
Vascular calcification can occur in the blood vessels, valves and cardiac tissues. 
Calcified deposits are found in distinct layers of the blood vessel and are related to 
underlying pathology. In general, vascular calcification can be categorized into four 
different types:  intimal calcification, medial calcification, valvular calcification and 
calciphylaxis (62). VC is a pathologic response to environmental stimuli, which triggers 
a multifaceted process that may arise by different pathophysiological, non-mutually 
exclusive, mechanisms (64). 
3.1.1.1 - Intimal Calcification 
Intimal calcification, also known as atherosclerotic calcification, is the most 
common form of calcific vasculopathy. The pathologic mineral deposition is associated 
with the recruitment of inflammatory cells, such as macrophages and lipid deposits 
within atherosclerotic plaques (65). 
Atherosclerotic microcalcifications are thought to derive from apoptotic VSMCs 
and from the accumulation of calcifying EVs within the internal elastic lamina (66). 
Moreover, macrophages associated with regions of calcified vascular structures have 
been shown to release EVs with high calcification and aggregation potential. (67). 
Atherosclerotic calcification is linked with myocardial infarction derived from 
stenosis or acute thrombus, and with ischemia in both coronary and peripheral arteries  
(68). 
3.1.1.2 - Medial Calcification 
Vascular calcification may also occur in the medial layer of the vessels, known as 
Monckeberg’s medial sclerosis. The most extensive vascular calcification is a highly 
characteristic feature found in patients with type 2 DM and CKD patients. This type of 
calcification is connected with increased risk of sudden cardiac death and lower limb 
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amputation due to vascular insufficiency, particular in type 2 DM and in end-stage renal 
disease (ESRD) (64).  
Medial calcification is characterized  by mineral deposition in the elastic lamina in 
the absence of classical atherosclerosis, this is, without lipid deposition and involvement 
of inflammatory cells (66). 
The pathogenesis of vascular medial calcification is thought to also recapitulate 
skeletal bone formation, with the involvement of VSMCs differentiation and the release 
of calcifying EVs (69). 
3.1.1.3 - Calcific uremic arteriolopathy 
Calcific uremic arteriolopathy (CUA), commonly known as calciphylaxis, is a 
severely morbid and life-threatening form of vascular medial calcification with different 
clinical manifestation depending on the organ involved. It is a pathology that affects 
small arterioles (<0.6 mm diameter) leading to profound skin ulcerations due to 
ischemia being associated with an extremely high mortality rate in dialysis patients (70). 
CUA is a condition with high morbidity and mortality, especially in ESRD 
individuals. Skin nodules and painful ulcers rapidly progress to black eschar and 
demarcating cutaneous necrosis within these patients. (64) 
3.1.1.4 - Cardiac Valve Calcification 
Calcification of cardiac valves involves the pathological mineralization of the 
cardiac valve leaflets causing life-threatening stenosis. Worldwide, population-based 
studies have revealed that aortic valve disease is the most frequently observed valve 
pathology in patients diagnosed with valvular heart disease, and thus is the most studied 
heart valve (71). 
Cardiac valve mineralization is similar to the vascular calcification process, 
including increased ECM degradation, differentiation of VSMCS and valvular 
intersticial cells, resembling physiologic mineralization in the bone tissue (69). 
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Figure  3.1 - Different types of vascular calcification. Vascular mineralization processes can  
occur in adventitia, media and interna layers within that vascular wall. It can also be observed in 
the leaflet of cardiac valves. Adapted from (72). 
3.1.2 - Vascular Calcification Mechanisms 
Vascular calcification has been widely described as a pathologic response to 
several stimuli (61). Although many aspects concerning the pathogenesis of VC are still 
uncertain, it is known that the base of this pathology comprehends multiple non-
exclusively mechanisms, such as proliferation and differentiation of resident VSMCs, 
loss of mineralization inhibitors, release of calcification competent EVs, VSMCs 
apoptosis, endothelial dysfunction, oxidative stress, increased extracellular matrix 
(ECM) remodeling, and chronic inflammation (73).  The synergistic effect of vascular 
calcification mechanisms is illustrated in Figure 3.2. 
3.1.2.1- Osteochondrogenic Differentiation 
Occasionally, structures that resemble bone tissue can be found in atherosclerotic 
lesions, suggesting that VC is an actively regulated process in which the vascular cells 
acquire osteoblast-like cell functions, ending up secreting osteoid-like matrix. Such 
finding, demonstrates that VC has a pattern that very much  resembles some processes 
of bone formation (74). As explained in the previous chapter, VSMCs exhibit a 
remarkable phenotypic plasticity, which allows them to switch from a contractile into an 
osteoblast-like state. 
In the cellular membrane vascular smooth muscle cells, have sodium-phosphate 
(NaPi) cotransporters known as PiT-1 and PiT-2, and calcium-sensing receptor (CaSR) 
as well voltage-activated channels (L and T type) that control phosphorus and calcium 
minerals entrance respectively, as illustrated in Figure 3.2. Recent studies have shown 
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that the initiation of calcification requires an increased uptake of Ca/P by VSMCs, 
which leads to a pattern of cellular adaptations and damage that ultimately promote 
calcification (75). Indeed, vascular calcification’s most devastating manifestation 
transpires in CKD due to dysregulated mineral metabolism, the main pathologic 
characteristic within this patients, that conducts to long-term elevation of serum Ca/P 
levels (76). Vascular smooth muscle cells exposed to elevated Ca/P minerals, present 
loss of their contractibility, and upregulation of  the expression of bone-related protein 
(osteochondrogenic expression) such as runt-related transcription factor 2 (Runx2), 
osteopontin, osteocalcin, alkaline phosphatase (ALP) ending up secreting calcifying 
EVs into the vessels ECM that promote mineralization sites and consequent 
calcification (47, 60). 
Despite several studies aiming at understanding the complex mechanisms of 
calcification, there are still several processes that need further clarification. Whether 
differentiation of VSMCs or the release of calcifying EVs occurs first is a debatable 
issue that needs additional elucidation (10).  
   3.1.2.2 - Loss of mineralization inhibitors 
 In a normal physiological environment, VC is controlled because VSMCs 
synthesize or uptake from circulation natural mineralization inhibitors, counterbalancing 
mineralization promoters and therefore preventing ectopic calcification. This balance, 
however, seems to alter in certain pathophysiological environments, such as the 
increased levels of Ca/P serum levels, resulting in downregulation of the expression of 
typical vascular calcification inhibitors, as illustrated in figure 3.2. Decreased 
expression or activity of VC inhibitors, creates a setting that favors mineralization (77). 
In literature, several molecules have been identified as potential mineralization 
inhibitors. Within these inhibitors, matrix gla protein (MGP), fetuin-A and Gla-rich 
protein (GRP) have been reported to have a role in the mechanism of vascular 
calcification involving EVs, and therefore their relevance will be further described in 
the next chapters. 
3.1.2.2.1 - Matrix- Gla Protein 
Matrix-gla protein is considered one of the strongest mineralization inhibitors 
known to date. It is a vitamin K dependent protein (VKDP) containing 5 γ -carboxylated 
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(Gla) residues in its mature form. These Gla residues have a high affinity to bind Ca as 
well as Ca/P mineral playing a vital role in vascular calcium metabolism (78,79). 
The γ-carboxylation process - where Glu residues are converted to Gla residues- is 
dependent upon vitamin K as a cofactor of the γ-glutamyl carboxylase (GGCX). This is, 
in order to MGP acquire its full calcification inhibitory activity, their Glu residues need 
to be converted to Gla residues by GGCX, in a vitamin K reaction dependent. This 
process, explains why vitamin K deficiency or the administration of high doses of 
vitamin K antagonists such as warfarin is associated with vascular calcification (80).  
Furthermore, studies conducted in MGP knock out mice showed that MGP-
deficient mice developed calcification of the arterial media at 1 week of age that rapidly 
progressed to encompass the entire media by 3 weeks of age, with consequent death by 
blood vessel rupture. MGP knock out mice are the strongest evidence of MGP role as a 
vascular calcification inhibitor (80). 
This protein is synthesized by both VSMCs and chondrocytes, and its anticalcific 
activity in both vasculature and growth plate is thought to be dependent on the presence 
of Gla residues, conferring to this protein high affinity for calcium and Ca/P mineral. It 
has been described that MGP calcium-binding Gla residues are capable of a direct 
interaction with calcium crystal thereby inhibiting its growth (78). Additionally, part of 
the anticalcific effect of MGP has also been attributed to its influence on bone 
morphogenetic protein 2 (BMP-2), preventing BMP-2 induced VSMCs differentiation 
(81). 
3.1.2.2.2 - Fetuin-A  
Fetuin-A, is a glycoprotein member of the cystatin superfamily, and has been 
recognized as a circulating inhibitor of vascular calcification. This cysteine protease 
inhibitor is synthesized abundantly during fetal development by multiple tissues, 
whereas in the adult, it is produced predominantly by the liver. Fetuin-A has a high 
affinity for HA and thus selectively accumulates in bone and teeth. This feature of 
fetuin-A explains the reason why it is also found within ectopic mineral deposits in the 
vascular wall and other calcified soft tissues. In circulation, fetuin-A binds to small 
clusters of Ca/P to form a soluble protein mineral particle, known as calciprotein 
particles (CPP) or fetuin-mineral complex (FMC). These CCP prevent further mineral 
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growth aggregation and precipitation (82). Circulating fetuin-A levels are reported to be 
reduced in patients with calcification (83) 
3.1.2.2.3 - Gla-Rich Protein 
Gla-rich protein, first described in sturgeon calcified cartilage, is the latest 
member of the vitamin K dependent protein family, recently shown to play a role as an 
inhibitor of vascular calcification (84). The unprecedented 15 putative Gla residues in 
human confer to GRP high calcium and mineral binding affinity, which allied to its 
pattern of tissue distribution in mammals and high vertebrates, suggest a critical 
function of GRP as a global calcium modulator (73).  Moreover it was shown that GRP 
is upregulated and accumulated at sites of ectopic mineral depositions, most likely due 
to its calcium chelator and mineral binding capacity (84). In blood vessels it was 
localized to VSMCs in the tunica media, and involved in VSMCs osteochondrogenic 
differentiation (85). 
3.1.2.3- VSMCs apoptosis 
Vascular smooth muscle cells apoptosis is also a mechanism that has been 
documented as another critical VC trigger. Prolonged cellular stress exposure by 
VSMCs conducts these cells into one of the following fates. They may differentiate to a 
bone-forming phenotype or undergo apoptosis when unable to adapt and respond to the 
extracellular mineral imbalance. A study conducted by Reynolds et al (86) demonstrated 
that the present of high Ca/P concentrations induced vesicle release by VSMCs. These 
EVs when isolated by differential centrifugation showed up to be two different vesicle 
subgroups. The smaller population, uniform in size, represented exosomes and the other 
population, composed by larger vesicles, had a size consistent with ABs. These findings 
suggest that increased P and Ca triggers nucleation of these ions into EVs that are 
released from both differentiated and apoptotic VSMCs. 
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Figure 3.2 - Mechanisms of vascular calcification. Ca/P dysregulation is the hallmark of 
vascular calcification, inducing multiple signaling pathways that increase the susceptibility of 
VSMC to calcification. ECM degradation (mostly by the action of MMPs), VSMCs 
differentiation, apoptosis and competent mineralization EVs release. Accumulation of 
mineralized EVs in ECM promotes the deposition of mineral crystal in the matrix. The direct 
effect of mineral deposition and growth leads to the mineralization of adjacent healthy VSMCs 
with propagation of vascular calcification. Adapted from (75). 
3.1.2.4 - Role of Calcifying EVs 
It is known that the earliest phase of vascular calcification pathology is 
characterized by the presence of mineralization competent EVs secretion that nucleates 
Ca/P crystals in a process that shares many similarities to that observed during skeletal 
mineralization (45). These EVs can be released by both differentiated and apoptotic 
VSMCs as exosomes or microvesicles and ABs, respectively (84, 54). Within the cargo 
of mineralization competent EVs, mineral crystals are formed, and later deposited in 
vascular ECM with the consequent propagation of matrix calcification. Recently, the 
capacity of EVs to be enriched with HA crystals has been correlated with the presence 
of annexins (ANXs) (88), and decreased levels of mineralization inhibitors (77,85) 
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within EV’s cargo content. This represents strong evidence that loss of molecular 
inhibitors to block mineral nucleation is crucial to increase EVs calcification 
competency, as illustrated in Figure 3.3. 
Under, physiologic vasculature conditions, VSMCs-derived EVs do not calcify 
because they are loaded with mineralization inhibitors, such as the ones described 
above, which prevent pathological calcification from occurring.  However, when a 
downregulation of these inhibitors occur in VSMCs, VSMCs-derived EVs start to 
become mineralization competent (calcifying EVs) by nucleation of HA crystals in a 
process that is actively controlled by ANXs and very much resembles physiologic 
mineralization in skeletal tissues (89).  
Prolonged exposure of VSMCs to elevated Ca/P, in the absence of fetuin-A, 
causes EVs to become mineralization competent (83). Additionally, GRP has been 
recognized as a new player in mineralization competence of EVs, associated with the 
Figure 3.3 - EV’s cargo content. Under physiological conditions, non-calcifying EVs are 
loaded with mineralization inhibitors, such as MGP, GRP and fetuin-A, preventing the 
formation of HA crystals. Under calcifying conditions, such as increased Ca/P levels, 
calcification-competent EVs are characterized by decreased levels of mineralization inhibitors 
and the formation of HA crystals, which once released into the extracellular space will be 
sequestered in the ECM promoting matrix mineralization. Dysregulated paracrine signaling 
results in an imbalance of calcification inhibitors and miRNA, leading to increased VSMCs 
osteogenic differentiation, with consequent vascular calcification. Adapted from (87). 
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fetuin-A-MGP calcification inhibitory system(85). Although the presence of a similar 
protein complex within EVs is still unknown, the association of these three proteins, 
with high calcification-inhibitory capacity, might represent a powerful ant 
mineralization system. 
Alongside with these studies highlighting decreased levels of mineralization 
inhibitors within calcification conditions, recent reports have identify selective 
enrichment of ANXs into EVs as an enhancer for  the mineralization competency of 
these vesicles (60,67).  
Annexins are calcium dependent phospholipid binding proteins that belong to an 
evolutionary well conserved multigene family, with members of the family expressed 
throughout animal and plant kingdoms. These proteins are widely found in EVs that are 
released from terminally differentiated chondrocytes to the surrounding extracellular 
bone matrix. Annexins are thought to initiate calcium influx into bone-derived EVs, 
promoting formation of HA crystals inside this vesicles and cartilage mineralization 
within the physiologic process of the bone tissue calcification (90). 
Interestingly, the ANXs isoforms ANX A2, ANX A5 and ANX A6, were 
identified inside calcifying EVs from blood vessels, with the particularity that A5 has 
been associated with macrophages-derived EVs and A6 with VSMC-derived EVs. 
Additionally, ANX A2 has been studied as a potential propagator of vascular 
calcification, by binding to fetuin-A, preventing this inhibitor from being  loaded into 
EVs in order to inhibit calcification  (89).  
Within the settings of vessels pathologic environment, calcifying EVs enriched 
with ANXs, and constantly nucleating Ca/P crystal in the form of HA, start to 
accumulate in the ECM  until they rupture and  release these crystals into the vessels 
matrix, creating the first nidus for mineral nucleation with subsequent ECM 
calcification (88).  
Indeed, EVs released into the ECM of blood vessels are crucial for VSMCs 
mineralization, since it can further induce osteochondrogenic differentiation and 
apoptosis in healthy VSMCs, promoting by itself more calcifying EVs release. Several 
individual or combinatorial inflammatory and non-inflammatory factors seem to 
influence the competence of these EVs for directing the mineralization process (60). As 
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demonstrated by Kapustin et al (88) , elevated serum of Ca/P, cytokines such as TNF-α 
and growth factors, increase EVs release. In opposition, IL-6, IL-10, and TGF-β1 
showed to decrease EVs secretion. Furthermore, alongside with the increase of 
inflammation mediators that promote calcification, there is normally the increase of 
MMPs that essentially promote the ECM degradation. This continuous ECM 
degradation process is a stimulus that further promotes more calcification. Additionally 
to this vicious cycle of propagating synergistically inflammation  processes, there has 
been recently demonstrated that inflammatory cells, like macrophages,  have the ability 
to also produce calcifying EVs (14), suggesting a direct contribution of these cells to 
vascular mineralization, with particular relevance in the atherosclerosis process (91). 
Nevertheless, epigenetic modulation regulating the dynamics of VSMCs gene 
expression plays a crucial role in the vascular tissue differentiation. Over the last decade 
RNA-based modifications, which alter the translation of genetic information, have 
emerged as important regulators of development and disease. As referred in the first 
chapter, EVs allow short and long distance delivery of cellular information including 
noncoding RNA and they appear to have an important role in the induction of VSMCs 
differentiation (32,37,38). 
3.1.2.4.1 - The emerging role of RNA 
The emerging role of RNA in intercellular communication and cardiovascular 
disease has given rise to a potential new perspective on vascular calcification triggered 
by EVs. Extracellular vesicles are well known vectors of biological information that can 
alter pathophysiological mechanisms in cardiovascular diseases by the transfer of either 
beneficial or deleterious mediators. Due to their varying cargo content, which include 
RNA, these vesicles can carry away an array of cellular signaling that can act as cellular 
regulatory signaling promoting the maintenance of homeostasis, or act as a potential 
trigger for the dysregulation of the cardiac system, with major implications in the 
initiating of vascular calcification (94). 
Accumulating evidence indicates that the incorporation of RNA in EVs allows 
these molecules to circulate in blood, avoiding extracellular degradation from blood 
RNAse activity, and mediate their transportation over local or long distances (22). 
Indeed, a number of reports have identified full-length and fragment protein coding-
RNA (mRNA) in EVs (90,91). In these studies, mRNA has been demonstrated to be 
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secreted by macrophages and glioblastomas derived-EVs, respectively, with a potential 
of directly modify gene expression with subsequent phenotypic modulation of adjacent 
cells.  
Although mRNA can have a direct influence in a cell’s phenotype, within the 
RNA species, miRNAs have been the most studied and the focus of recent researches. 
MiRNAs are a large class of evolutionarily conserved, small, endogenous, noncoding 
RNAs that function as crucial modulators of gene expression MiRNAs have 
complementary sequences in messengers RNAs (mRNAs) (94). Depending on the 
abundance of a miRNA and its targets, as well as the physiological state of a cell, 
miRNA regulate gene expression as an on/off switch button, having a profound impact 
in the cells phenotype (97). 
 In one hand, one single miRNA may target multiple genes, providing extensive 
translation regulation. On the other hand, multiple miRNAs can also work together to 
promote combinatorial regulation by individually aiming  several components of the 
same gene transduction pathway, indicating a remarkable redundancy in the system 
(98). 
Although EVs-derived miRNAs have received little attention in vascular 
calcification, recent data suggests that some miRNAs might actually be new potential 
players in the triggering of the VSMC’s differentiation process, by direct influence on 
the expression of a specific set of osteogenic markers such as Runx-2, ALP, osterix, 
osteocalcin and msh homeobox 2 (Msx2) in healthy VSMCs. Furthermore, it has been 
proposed that EVs loaded with miRNA may become trapped at sites of vessels 
inflammation and calcification, thus preventing miRNAs packed into EVs from 
reaching the intended target cell and triggering an unwanted local phenotypic change in 
VSMCs that contributes to the beginning or further growth of microcalcifications (99).  
Insight into the underlying mechanism of selective packaging of miRNAs into 
EVs and selective uptake in the target cell represents a promising field that once 
elucidated will open clinical opportunities to promote timely intervention and 
prevention for vascular calcification (100), as discussed in the next chapter.
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4 - Clinical Role of Extracellular Vesicles in Cardiovascular 
Disease 
4.1 - EVs-mediated Delivery of Therapeutic Biomolecules 
The introduction of EVs as mediators of vascular matrix mineralization marked 
the discovery of an essential mechanism in the pathogenesis of cardiovascular disease. 
As the connection between calcifying EVs and vascular calcification proceeds to gain 
recognition, a number of emerging clinical applications regarding EVs potential 
therapeutic role in this pathology is growing very fast.  
The field of drug delivery and gene therapy rely on nano sized carriers for 
effective delivery of their cargo to the desired target sites. Therapeutic delivery agents 
have two key objectives: protect cargo from the severe environment of the body and 
release cargo at the appropriate site with decreased  immunogenic response (101). In 
order to achieve these goals, both viral and non-viral nano carriers have been engineered 
to accomplish effective, site specific drug delivery. While viral delivery has been used 
to delivery genes to target cells with relatively high efficiency, non-viral carriers, such 
as nanocarbon assemblies (102), inorganic nanoparticles (103), and liposomes (104) 
gain by their lower potential for inducing side effects. 
Normally, issues associated to non-viral carriers such as  non-specific 
cytotoxicity, decreased drug circulation times and increased immunogenicity, have been 
overcome by PEGylation process (105). However, recent studies have shown rapid 
clearance of PEGylated carriers after the initial injection as a result of systemic 
immunogenicity (106).  
In fact, the only option for completely eliminating the potential of immune 
response is to use nano carriers derived from a patient’s one body. Therefore, EVs have 
recently become an exciting option for nanoscale delivery, by offering a compelling 
opportunity to develop personalized therapeutic delivery carriers. Recently, it was 
demonstrated that VSMCs mineralization is mediated by regulated exosome secretion 
indicating the modulation of the exosome release pathway as a novel therapeutic target 
for the prevention of vascular calcification (60). 
It has been shown that biological information in EVs, like their content in nucleic 
acids, lipids and proteins can be transferred between cells and thus alter the recipient 
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cell’s phenotype (see section 1.1.1). The ability of EVs to transfer their content to 
recipient cells via endogenous uptake mechanisms makes them attractive candidates for 
application in drug transportation as a new drug delivery system. Moreover, since EVs 
content reflects the status of its donor cell, these nanoparticles may also be applied in 
diagnostics, either as pathological biomarkers or to follow up treatment efficacy (107). 
Potential advantages of EV-based drug delivery over the existing delivery systems 
make them a suitable superior choice. These include EV’s ability of containing proteins 
and genetic material, with decreased immunogenicity carrying no apparent risk of 
toxicity, long half-life with increased stability in circulation and tissues, the ability to 
overcome natural barriers, like plasma membranes and to release their contents within 
target cells. More importantly, due to EVs intrinsic homing ability, relatively to 
synthetic particles, their unwanted accumulation in organs other than the target tissue is 
avoided (108,109).   
Although the mechanisms of calcifying EV release are still insufficiently 
understood, the recent emergence of novel regulators like fetuin‐A, MGP, GRP, ANXs 
and RNA species may be a major step forward in the search for potent therapeutic 
targets, as well as biomarkers, for cardiovascular diseases. Additionally, although the 
presence of a protein complex involving the three above mineralization inhibitors within 
EVs is still uncertain, the association of these proteins, with high calcification-inhibitory 
capacity, might represent a powerful anti- mineralization system. 
Recent data demonstrated that under calcifying condition, secreted EVs showed 
increased calcium loading alongside with GRP and MGP depletion (85), highlighting a 
potential therapeutic strategy by the loading of these proteins into EVs. Additionally, 
GRP detected at protein and mRNA in macrophages-derived EVs, has been proposed to 
act as a novel mediator of inflammatory responses, acting as an anti-inflammatory agent 
in macrophages, linking inflammation with calcification, with potential clinical 
application (110). 
In order to be used as carriers for specific cargo, successful application of EV 
therapeutics is entirely dependent upon the extent of cargo loading. Despite EVs hold 
immense promise for therapeutic drug delivery, its clinical application still need further 
study, with a special focus on the development of scalable EVs isolation techniques and 
approaches for efficient drug loading. Additionally, improved methods to modify 
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biodistribution of EVs in vivo, are also required, since it is an important determinant of 
their therapeutic effect, in order to enable more specific drug delivery to target tissues 
(111). Currently, there are two general processes for loading therapeutic cargo within 
EVs: endogenous and exogenous loading. 
4.1.1- Endogenous Drug-Loading Mechanisms 
Endogenous loading implies the addition of therapeutic cargo to the EV directly 
from the donor cell. That is, the therapeutic cargo within donor cell is directly into the 
EV, prior to its shedding. The most commonly used type of endogenous loading 
includes RNA loading into the EV following expression from a vector. In 2011, a study 
conducted by Akao et al (112) demonstrated that transfected RNA molecules in human 
monocytes could indeed be shed from macrophages derived-EVs.  
Another form of endogenous loading is the cell extrusion method, in which 
vesicles are produced artificially by breaking up the cells and posterior reforming of 
their contents into exosome mimetic. This exosome mimetic formation technique, 
developed by Su Chul Jang (113), has demonstrated a successful delivery of 
chemotherapeutics, such as doxorubicin, to mouse colon adenocarcinoma, after 
systemic administration. In one step further, a third mechanism of endogenous loading 
using hybrid vesicles, referred as “vexosomes”, has associated viral packaging systems 
with exosomes. Vexosomes combine the desirable features of both EVs and adeno-
associated virus vector systems, providing enhanced transfection efficiencies in the 
recipient cells at the same time that EVs protects the vector from neutralizing antibodies 
in vivo (114).  
The primary advantages of endogenous loading include having a complete cellular 
system that is scalable and the therapeutic cargo directly loaded into the drug delivery 
system (EVs). This offers the potential for substantial cost savings, since therapeutic 
cargo is expressed from the donor cell. However, the disadvantage of this mechanism is 
the low cargo loading efficiencies into EVs, while the loading efficiency for exogenous 
methods can be quite higher (115). 
4.1.2- Exogenous Drug-Loading Mechanisms 
Exogenous methods are much more common in literature and include the loading 
of therapeutics within EVs after they are isolated. These methods can be further 
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subdivided into passive and active loading. Although these strategies require additional 
purification processes in comparison to loading EVs via their parent cells (endogenous 
loading), they often produce more efficient loading outcomes (116). 
Passive loading is the simplest method of introducing a therapeutic of interest into 
EVs. The strategy involves incubating the isolated EVs with the therapeutic and then 
purifying the EVs post-loading. Passive loading includes cholesterol conjugation, and 
simple drug incubation methods. Recently, Saari et al (117) described passive loading 
of prostate cancer cell derived exosomes with Paclitaxel, revealing that the use of these 
delivery systems improved the cytotoxicity of chemotherapy by taking advantage of the 
endocytic pathways of these vesicles. 
Active loading refers to strategies that enable more efficient penetration of 
therapeutic through the lipid bilayer than exclusive incubation. These strategies 
comprehend electroporation, saponin permeabilization and hypotonic dialysis. 
Electroporation, which increases the permeability of the EV membrane by applying 
electric pulses, is perhaps the most common active loading strategy applied to EVs. The 
disadvantage of exogenous loading is the introduction of additional steps to the 
manufacturing process and in the case of nucleic acid delivery, the need for expensive 
chemically modified oligonucleotides (118). A study conducted by Fuhrmann et al 
(119) used electroporation in order to employ porphyrins of different hydrophobicities 
as model drugs to be encapsulated into EVs. In this study was showed that these 
compounds loaded very efficiently into vesicles and at significantly higher amounts that 
into standard liposomes. Furthermore, the use of EVs as drug carrier increased the 
cellular uptake of porphyrins when compared to liposome drug delivery system. 
From a pharmaceutical perspective, the reproducibility of EVs composition and 
purity is particularly demanding because their cargo is associated with different classes 
of biomolecules, each of them divided into hundreds of species inside their own class 
which together contribute to the overall effects within the recipient cell. Overcome these 
current obstacles becomes important since the identification of the active agents in the 
EVs composition dictates quality control and  therapeutic efficacy (120). 
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4.1.3 - Therapeutic Delivery of Nucleic Acid-Based Drugs  
Extracellular vesicles carry multiple types of molecules including proteins and 
nucleic acids, and these cargoes are more stable than they would be if exposed to body 
fluids, particularly in the case of mRNA and miRNA. In various disease conditions, the 
profiles of circulating RNA species vary according to the degree of the disease, and 
while some of them promote the development of CVD, others seem to have a protective 
role (121). Recently, treatment options including EVs loading with anti-miRNAs 
(miRNA inhibitors) and miRNA-mimics (synthetic miRNA replicas), which 
respectively destroy or potentiate  miRNA physiologic functions involved the 
cardiovascular system, have been in focus (122). However, due to the ubiquitous 
occurrence of miRNAs and its many different functions in cells, the identification of an 
appropriate miRNA target remains difficult (111). 
Interestingly, exosomes have been recently shown to improve cardiac function in 
a rat ischemia  reperfusion  injury model as they led to reduced cardiomyocyte apoptosis 
and improved  left ventricle ejection fraction (123). Further studies demonstrated that 
intravascular injection of endothelial EVs containing miRNA-126, accelerated re-
endothelialization after electric denudation of the endothelium in vivo (124). Taken 
together, these findings illustrate the fundamental relevance of miRNA-delivering by 
EVs for preserving physiologic conditions in the body. In addition to its physiological 
roles in maintain cell homeostasis, the dysregulation of miRNA often leads to impaired 
cellular function and disease progression, pointing that they can in fact orchestrate the 
mal functioning of the cardiovascular homeostasis (125). Sun et al (126),  expanded the 
knowledge about influences of miRNAs on atherosclerotic development by showing 
that circulating mi-RNA181b is markedly reduced in plasma of human subjects with 
coronary artery disease. 
Furthermore, despite the basic mechanisms that trigger VSMCs phenotypic 
modulation are still debatable, it seems that this phenotypic switch likely depends on 
signals from the surrounding environment. Even though miRNAs are crucial for the 
VSMCs homeostasis, when its transport is compromised by environmental stimuli, they 
start to perform a dysfunctional role on target cells, triggering a cascade of events that 
ultimately culminates in the genesis of a pathology, like vascular calcification. Within 
this thought of knowledge, several studies have recognized miRNAs as important 
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mediators for the modulation of VSMCs phenotype. MiRNAs have been shown to 
targeting transcription factors that act as molecular switches for VSMCs differentiation 
through the up or downregulation of signaling pathways that promote a synthetic 
phenotype. Moreover, miRNA-204 has been demonstrated to be suppressed in mouse 
aortic VSMC during induced calcification, whereas Runx2 protein levels were elevated. 
A promising result was achieved after the overexpression of miRNA-204, by 
transfection of miRNA-204 mimics, which lead to decreased levels of Runx2 levels and 
alleviate osteochondrogenic differentiation of VSMCs  (127). Other study conducted in 
mouse VSMCs (MVSCMs), showed that the increased expression of miRNA-32 was 
correlated with the promotion of MVSMCs calcification by inducing expression of 
vascular calcification markers. It was determined that  the transfection with miRNA-32 
mimic markedly increased miRNA-32 levels in MVSMCSs and promoted the 
expression of Runx2, osteopontin, BMP-2 (128). 
More recently, Panizo et al (100) induced aortic calcification by feeding 
nephrectomized  rats a normal or high-phosphorus diet, and  further analyzed eight 
miRNA within the aorta. Using anti-miRNA and miRNA-mimics for miRNA-29b, 
miRNA-133b, and miRNA-211 they studied the expression levels in these models and 
confirmed that these miRNAs regulate the calcification process, with direct roles in 
VSMCs calcification. It was proved that low levels of miRNA-133b and miRNA-211 
and higher levels of miRNA-29b correlated respectively with greater expression of 
osteogenic Runx2 and with lower expression of several inhibitors of osteoblastic 
differentiation, leaving promising evidence that these miRNAs may be new therapeutic 
targets in the management of vascular calcification. 
The previous studies associated with the constant increase of published papers 
highlighting the pertinent role of some miRNAs in the promotion of vascular 
calcification, makes no doubt about considering EVs as a very promising therapeutic 
choice in the treatment of cardiovascular diseases via the transportation of these 
molecules. A study conducted by Nguyen et al (129) demonstrated that EV-derived 
miRNAs from macrophages, in particular miRNA-146a, may accelerate the 
development of atherosclerosis by decreasing cell migration and promoting macrophage 
entrapment in the vessel wall. 
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 Copying the action of EVs by engineering vesicles to express specific molecular 
anchors in its cellular membrane and bioactive material within its cargo, will probably 
constitute a future therapeutic option to target specific cells in order to prevent or limit 
cardiovascular outcomes of vascular calcification (9).  However, in order to success the 
achievement of this promising pharmacological therapy, future work addressing all 
advantages of EV-bound miRNAs and filling the gaps in our current knowledge of EV’s 
cargo in calcific plaque must be done (111). 
4.2 - Extracellular vesicles as promising biomarkers 
One of the major challenges in clinical pathology is the identification of suitable 
biomarkers that reliably indicate a disease state. The characterization of EVs in several 
body liquid fluids, such as blood, is an underestimated source of biological information 
regarding cellular activation during disease progression (97). Indeed due to their cargo 
content, EVs have been recently the focus of several studies, not only as a promising 
drug delivery systems but as well as potential biomarkers of CVD.   
In a study conducted by Kapustin et al, MGP and ANX A6 were shown to be 
present in VSMCs-derived EVs in calcification promoted by calcium imbalances, 
revealing a promising utility of these EVs contents as biomarkers of calcification (88). 
Furthermore, beside the use of GRP as a possible therapeutic choice, it has also been 
highlighted its role as a promising biomarker, since several studies have demonstrated 
its depletion in EVs cargo within vascular calcification settings (73,85). 
Moreover, miRNAs loaded into EVs have been shown as suitable molecules for 
biomarker utility, particularly due to its features of, good sensitivity and specificity; 
noninvasive measurability; long half-life within the samples; and time-related changes 
during the course of disease. Several studies have reported altered levels of miRNA 
within some cardiovascular diseases, highlighting the potential use of these molecules 
as biomarkers for the pathologic states. An in vivo study, showed that cardiac damage 
initiates the detectable release of cardiomyocyte-specific miRNA-208b and miRNA-499 
into the circulation, further demonstrating that circulating miRNA-499 is significantly 
increased in patients with acute heart failure (130). Another in vivo study, demonstrated  
that decreased plasma levels of miRNA-150 were significantly associated with atrial 
fibrillation within the studied patients (131). Furthermore, Yang et al (132), conducted a 
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study in order to detected and analyzed plasma samples from three independent cohorts 
to identify circulating miRNAs candidates in essential hypertension patients. The final 
results indicated that the plasma miRNA-505 was significantly elevated in essential 
hypertensive patients.  
Correlating these documented studies, highlighting the importance of miRNAs in 
cardiovascular diseases, with the increased knowledge of EVs containing these RNA 
species is opening doors for the development of researches focusing on miRNA loaded 
EVs as new biomarker molecules. However there is currently no biomarker available 
for vascular calcification.  
Furthermore some problems regarding the use of these molecules as biomarkers 
need to be ungently solved. Firstly, the majority of samples of the studies aimed to 
identify circulating miRNAs as biomarkers of cardiovascular diseases are relatively 
small. There is then the need of having the conclusions validated in independent and 
large cohort studies. Secondly, the expression profiles of circulating miRNAs change 
depending on the disease state, which makes it difficult to determine appropriate 
endogenous controls. Thirdly, RNA isolation from blood samples and subsequent 
quantification by real-time PCR is a time consuming methodology (9). 
Nevertheless, circulating miRNAs are emerging as the next generation “smart” 
biomarkers for numerous pathologic conditions. And although at the moment however, 
no circulating biomarker is available for the diagnosis of VC, much work is published in 
order to achieve a suitable molecule that can serve as a reliable cardiovascular disease 
biomarker. From a clinical perspective, understanding the details of the surface 
proteome of EVs is essential for developing biomarkers for disease. In fact, the finding 
of a serum biomarker of early vascular calcification that could be used in both 
diagnostic and prognostic would be a great technological progress (9). 
Within this field, major repercussions would result from a strong research effort to 
establish procedures to isolate EVs subpopulations in liquid biopsies since the presence 
of contaminants in EVs isolated by the current methods is a major disadvantage in EVs 
molecular profiling and biomarker studies. Moreover sensitive techniques that can 
detect slight miRNA differences in serum levels are still required for further 
interpretation of the miRNA roles implicated in EVs-mediated VC (133).
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5 - Conclusion 
In the last decade, the number of studies recognizing EVs as a crucial and integral 
part of cellular microenvironment and communication has grown exponentially 
revealing a new scenario in terms of understanding signal and molecule transfer 
between cells, not only locally, but also over long distances. 
However, although recent advances, there is still much to clarify by EVs scientific 
community. One of the most urgent challenges right now is to establish methods to 
separately isolate and purify EVs in order to clearly characterize each EVs subtype  
through the identification of their individual membrane receptors, cargo and functions, 
as well as to determine whether some of their functions are specific or prominent in a 
given subtype. Furthermore, due to the fact that much of the knowledge regarding the 
role of EVs in cardiovascular calcification relies heavily on previously established 
evidence of MVs involved in physiological bone mineralization, the terms 
‘‘extracellular vesicles’’ and “matrix vesicles” have been used interchangeably in many 
published studies.  
The introduction of EVs as mediators of vascular ECM mineralization marked the 
discovery of an essential mechanism in the pathogenesis of cardiovascular disease. 
Vascular calcification is no longer simply recognized as an inevitable consequence of 
aging. Currently established as an active and highly complex process that cannot be 
ignored in patient’s cardiovascular clinical health, VC has been linked to the presence of 
mineralization competent EVs. Extracellular vesicles released to the ECM of blood 
vessels, are proved to represent the first nidus for mineral nucleation, promoting the 
mineralization of the vessels matrix and propagation of vascular calcification. 
Additionally, the presence of microcalcifications is by itself a trigger for the increasing 
of inflammatory factors that promote inflammation sites correlated with VSMCs 
differentiation, with a recent discover that macrophages can be involved in 
inflammation settings, secreting as well calcifying EVs. 
Promotion of the EVs competency for mineralization has been largely associated 
with decreased levels of calcification inhibitors such as MGP, GRP and fetuin-A, as 
well as with the presence of annexins within EVs cargo. Furthermore, recent findings 
that RNA species enclosed into EVs can mediate the phenotypic modulation of VSMCs, 
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have expanded the knowledge regarding the role of vesicles in EVs-mediated 
calcification. 
Understanding the connection between the role of calcifying EVs and the 
pathogenesis of vascular calcification is opening doors for the developing of clinical 
applications regarding EVs as these vesicles have the potential to be diagnostic 
biomarkers or used as treatment vectors. Furthermore, given the problems associated 
with many of the current non-viral delivery systems, from which stand out liposomes, 
the potential advantages of EVs as natural carriers of cellular information allied with its 
intrinsic home ability, make them a promising superior choice. 
The loading of calcification inhibitors proteins, such as MGP,GRP and fetuin-A 
has been acknowledged as promising circulating biomarkers for vascular calcification. 
Additionally, as they are well known recognized proteins in EVs cargo, the 
development of therapeutic strategies using EVs loading mechanisms with these 
calcification inhibitors is currently in its humble beginnings. Moreover, gene therapy for 
cardiovascular diseases has seen great advancement in terms of vector design and gene 
delivery methods, that allied with EVs inner properties of shipping RNA species 
throughout the body, will be with no doubts a future clinical weapon against 
cardiovascular diseases. 
However, still, an immense amount remains to be learned, particularly about how 
information flows through cells and how they decide on the most appropriate ways to 
respond. EVs-mediated vascular calcification is a vexing mechanism that is 
unquestionably correlated with several pathological processes occurring in the vessels 
wall.  In order to clarify the role of EVs in this pathology and speed up the use of 
vesicles as the next generation of targeted gene delivery vehicles, protocols to obtain 
high quality, high purity, and large scale EVs need to be developed and uniformly used 
among researchers in order to ensure that the documented characterization can remain 
comparable across different laboratories. Furthermore, technologies of efficiently 
loading therapeutics into vesicles need to be developed and standardized.  
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